Meronem and flagyl
Small molecule
Meronem and flagyl is one of 32 small molecule programs targeting Appendicitis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Appendicitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Flagyl
DDePuy Orthopaedics
Approved
Ketalar
AAultman Health Foundation
Approved
Merrem
BB. Braun Medical Inc.
Approved
Betadine
BBecton, Dickinson and Company
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Marcaine
IInnocoll
Approved
Monurol
MMeitheal
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Meronem and flagyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- KKing Edward Medical University